{"disease":{"id":"lower-resp-tract-infection","name":"lower resp tract infection"},"drugs":{"marketed":[{"drug_id":"cefoxitin","indication_name":"Lower respiratory tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Lower respiratory tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"ceftazidime","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"amoxicillin-and-clavulanate","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicillin and clavulanate","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},{"drug_id":"chembl-chembl3989564","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cefuroxime-sodium","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"cefradine","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefradex","generic_name":"cefradine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefradine","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"cefapirin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefaprin","generic_name":"cefapirin","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"cefapirin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"cefazolin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFAZOLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefazolin-sodium","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"Cefazolin Sodium","company_name":"GSK","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":60,"revenue":null,"mechanism":"Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"vancomycin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefotaxime","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cloxacillin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methocillin S","generic_name":"CLOXACILLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"cloxacillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime-axetil","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"metronidazole","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"amoxicillin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"ciprofloxacine","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cefamandole","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftriaxon","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"aztreonam","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"imipenem","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefonicid","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monocid","generic_name":"CEFONICID","company_name":"","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefonicid","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefotetan","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefotan","generic_name":"CEFOTETAN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cilastatin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"cefalotin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cephalotin","generic_name":"cefalotin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 8","drug_class":"cefalotin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"tazicef","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"norfloxacin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cefmetazole","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zefazone","generic_name":"CEFMETAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Insulin-degrading enzyme","drug_class":"cefmetazole","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"oxacillin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cephradin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephradin","company_name":"Sohag University","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cephazolin","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephazolin","company_name":"HaEmek Medical Center, Israel","drug_phase":"phase_1","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cefazoline","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefazoline","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Lower respiratory tract infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":45,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03694392","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","phase":"","overall_status":"COMPLETED","enrollment_count":2776278,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT07416266","title":"Lower Respiratory Tract Infections Managed in Primary Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":230066,"lead_sponsor_name":"Hôpital Raymond Poincaré","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04320862","title":"COVID-19 Pandemic Response Network","phase":"","overall_status":"COMPLETED","enrollment_count":9207,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT02130986","title":"Procalcitonin Antibiotic Consensus Trial (ProACT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1664,"lead_sponsor_name":"University of Pittsburgh","has_results":true},{"nct_id":"NCT02979626","title":"Evaluation of Moderate to Severe Influenza Outcomes in Children","phase":"","overall_status":"COMPLETED","enrollment_count":1478,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT03392363","title":"Diagnosing Respiratory Disease in Children Using Cough Sounds 2","phase":"","overall_status":"COMPLETED","enrollment_count":1470,"lead_sponsor_name":"ResApp Health Limited","has_results":false},{"nct_id":"NCT05463406","title":"Procalcitonin and Lung Ultrasonography Guided Antibiotherapy in Emergency Departments","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1440,"lead_sponsor_name":"Dr Boillat-Blanco Noemie","has_results":false},{"nct_id":"NCT05762302","title":"The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) (\"JUPITER\" TRIAL)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1316,"lead_sponsor_name":"MeMed Diagnostics Ltd.","has_results":false},{"nct_id":"NCT04829188","title":"Comparative Effectiveness of Readmission Reduction Interventions for Individuals with Sepsis or Pneumonia","phase":"NA","overall_status":"COMPLETED","enrollment_count":1288,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT05937126","title":"Rapid Diagnostic Supporting Antimicrobial Stewardship in Patients With Pneumonia","phase":"","overall_status":"COMPLETED","enrollment_count":1203,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07249996","title":"Respiratory Infections in Young Children","phase":"","overall_status":"RECRUITING","enrollment_count":1088,"lead_sponsor_name":"Eduardo Lopez -Medina","has_results":false},{"nct_id":"NCT04357366","title":"suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Hellenic Institute for the Study of Sepsis","has_results":false},{"nct_id":"NCT03756753","title":"The RAPID Trial: Assessing Point-of-care Influenza and Other Respiratory Virus Diagnostics","phase":"NA","overall_status":"COMPLETED","enrollment_count":913,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT07382219","title":"Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants","phase":"","overall_status":"COMPLETED","enrollment_count":816,"lead_sponsor_name":"Han Tongyan","has_results":false},{"nct_id":"NCT05110261","title":"Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03391076","title":"The Clinical Value of FA in AHLRI Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Bin Cao","has_results":false},{"nct_id":"NCT03011515","title":"Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)","phase":"","overall_status":"COMPLETED","enrollment_count":583,"lead_sponsor_name":"MeMed Diagnostics Ltd.","has_results":false},{"nct_id":"NCT06016244","title":"Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: a Randomized Controlled Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":560,"lead_sponsor_name":"Spaarne Gasthuis","has_results":false},{"nct_id":"NCT03341273","title":"Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level","phase":"NA","overall_status":"TERMINATED","enrollment_count":514,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05423847","title":"Triage UltraSound in Tb Endemic Regions","phase":"","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false},{"nct_id":"NCT03191071","title":"An Algorithm to Decide on Antibiotic Prescription in Lower Respiratory Tract Infection in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":469,"lead_sponsor_name":"Centre Hospitalier Universitaire Vaudois","has_results":false},{"nct_id":"NCT03460171","title":"Clinical Features, Outcome and Prognosis of Human Metapneumovirus (hMPV) Lower Respiratory Tract Infections in Adult Inpatients","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06210282","title":"The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":391,"lead_sponsor_name":"Aalborg University","has_results":false},{"nct_id":"NCT03808922","title":"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":274,"lead_sponsor_name":"Ansun Biopharma, Inc.","has_results":false},{"nct_id":"NCT01735084","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":261,"lead_sponsor_name":"Menzies School of Health Research","has_results":false},{"nct_id":"NCT04233268","title":"RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT07417657","title":"Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Phuc Huu Phan","has_results":false},{"nct_id":"NCT06294899","title":"CRP and Lung Ultrasound in Respiratory Evaluation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":202,"lead_sponsor_name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","has_results":false},{"nct_id":"NCT03379779","title":"Evaluation the Association of Microbiome Between Respiratory Tract Samples and Stool Samples in Pneumonic Patients Accompanied by Respiratory Failure","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT07381790","title":"Modern Technologies in Lower Respiratory Tract Infections in Children","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Helse Møre og Romsdal HF","has_results":false},{"nct_id":"NCT06636890","title":"Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT02979431","title":"Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Ablynx, a Sanofi company","has_results":true},{"nct_id":"NCT04602234","title":"Diagnostic of Lower Respiratory Tract Infection by Lung Ultrasonography in General Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05380869","title":"POCT PCT in Outpatient LRTI","phase":"NA","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT06960044","title":"Procalcitonin Aided Antimicrobial Therapy vs Standard of Care","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria","has_results":false},{"nct_id":"NCT06211985","title":"Copeptin: Disease Severity Indicator","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Berker Okay","has_results":false},{"nct_id":"NCT06201494","title":"Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Charles University, Czech Republic","has_results":false},{"nct_id":"NCT06156436","title":"A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Paediatric Patients in an Emergency Department","phase":"","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"ResApp Health Limited","has_results":false},{"nct_id":"NCT07279675","title":"Clinical Predictors of Severity in Pediatric Community-Acquired Pneumonia at Assiut University Children's Hospital","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":67,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07183553","title":"The Effect of a Family-Centered Care Approach on Infants Receiving High-Flow Nasal Oxygen Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT06149494","title":"RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Altesa Biosciences, Inc.","has_results":false},{"nct_id":"NCT04225897","title":"A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04311320","title":"A Low-Resource Oxygen Blender Prototype for Use in Modified Bubble CPAP Circuits","phase":"NA","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT01952470","title":"Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"The Alfred","has_results":true},{"nct_id":"NCT06668883","title":"Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study","phase":"","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Avelo AG","has_results":false},{"nct_id":"NCT05374070","title":"Antiviral Activity of Oral Probiotics","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"John Hale","has_results":false},{"nct_id":"NCT03418571","title":"Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Ablynx, a Sanofi company","has_results":true},{"nct_id":"NCT03915236","title":"Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection","phase":"NA","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","has_results":false},{"nct_id":"NCT04267822","title":"Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}